Korea Research Institute of Bioscience and Biotechnology Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2013
NCT01795378
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Korea Research Institute of Bioscience and Biotechnology

Active Ingredients

Drugs in Phase 2 Trials (1)

allogeneic natural killer cells (2 trials)

Drugs in Phase 1 Trials (1)

pemetrexed (alimta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2